Your local and state governments, as well as the Federal government, each play an integral role in enacting and implementing policy that affects the health and well-being…
Written by Jennifer Huron on April 5, 2017
Lawmakers are currently considering legislation to reauthorize FDA user fees. The FDA largely relies on user fees to operate and review innovative drugs, biologics, and devices. Not only does this legislation provide critical funding for FDA to quickly review products, but the user fee agreements also provide patients and… Read More
Written by Jennifer Huron on September 22, 2016
More than 300 organizations join forces to ask Congress to provide robust, sustained, and predictable budget increases for the NIH
Washington, D.C., September 22, 2016—… Read More
Written by Jennifer Huron on April 28, 2015
Paul Melmeyer, NORD’s Assistant Director of Public Policy, attended the FDA’s public meeting on Chagas Disease Patient-Focused Drug Development on April 28. Chagas is a rare parasitic disease (read NORD’s Rare Disease Report here) that is spread by insects. While it… Read More
Written by Christina Jensen on March 16, 2015
NORD’s Assistant Director of Public Policy, Paul Melmeyer, authored this great piece (below) in the March 2015 issue of the NCC Collaborator, the monthly publication from the National Coordinating Center for the Genetic Service Collaboratives (NCC). NCC focuses on bringing quality genetic and newborn screening services to local communities, and… Read More
